Processa buys Vidya, raises ~$200M to push BTK inhibitor into three trials
What's the deal? Processa PharmaceuticalsDealroom has a profile for this one. Try Dealroom → (Nasdaq: PCSA) has acquired clinical-stage biotech Vidya TherapeuticsDealroom has a profile for this one. Try Dealroom → and simultaneously raised roughly $200 million in an oversubscribed private placement. The financing came from a syndicate of new and existing healthcare investors.
The acquisition: The deal brings Vidya's lead asset, VT-7208, into Processa's pipeline. It is a next-generation, CNS-penetrant, once-daily oral Bruton's tyrosine kinase (BTK) inhibitor designed to overcome the efficacy and safety limits of earlier BTK inhibitor programs.
Who's backing it? Investors include Bain Capital Life SciencesDealroom has a profile for this one. Try Dealroom →, Janus Henderson Investors, RA Capital Management, SilverArc CapitalDealroom has a profile for this one. Try Dealroom →, ADAR1 Capital ManagementDealroom has a profile for this one. Try Dealroom →, Cormorant Asset Management, Integral Health Asset ManagementDealroom has a profile for this one. Try Dealroom →, Marshall WaceDealroom has a profile for this one. Try Dealroom →, Octagon CapitalDealroom has a profile for this one. Try Dealroom →, Soleus CapitalDealroom has a profile for this one. Try Dealroom →, and a large mutual fund.
What's the money for? Processa plans to run three Phase 2 proof-of-concept studies in parallel — targeting food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS). Food allergy data is expected in the second half of 2027, CSU data in the first half of 2028, and RMS data in the second half of 2028.
Why now? The proceeds are expected to fund operations into the second half of 2029 and through those key clinical milestones. That runway lets Processa test VT-7208 across three indications at once rather than sequentially.
The key hire: Sheila GujrathiDealroom has a profile for this one. Try Dealroom →, founder and executive chair of Vidya, joins Processa's board as a director. "This transaction gives us the capital to evaluate VT-7208's potential, running our food allergy, CSU and RMS programs in parallel rather than sequentially," she said.
The signal: A small-cap acquiring a private developer alongside a $200 million raise from top-tier funds shows continued appetite for differentiated BTK inhibitor programs targeting large, underserved immune-mediated diseases.
Read more: GlobeNewswire
